6/5/2024, 12:07:00 PM | www.prnewswire.com | news
TOPIX Pharmaceuticals, Inc. Partners with the University of Minnesota, Center for Drug Design to Develop Groundbreaking ProteXidine Molecule
TOPIX Pharmaceuticals, Inc. has partnered with the University of Minnesota's Center for Drug Design to develop ProteXidine™, a biomimetic decoy molecule that enhances the skin's ability to manage UV-induced damage and inhibit the production of Reactive Oxygen Species (ROS). This innovation, resulting from nearly a decade of research, aims to prevent premature aging and reduce the risk of skin cancer by clearing Cyclobutane Pyrimidine Dimers (CPDs) and maintaining collagen density. The collaboration highlights TOPIX's commitment to scientific innovation in skincare.